Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The firms partnered to develop haemophilia medications with projected sales potential of $1bn over the next 10 years; Ipsen committed up to US$259m of funding…
Inspiration files Chapter 11 to pursue strategic transaction; Ipsen provides DIP financing while joint sale process is launched for OBI-1 and IB1001.
Baxter scoops up OBI-1 from Ipsen and bankrupt Inspiration in deal worth up to $700M — ending the Ipsen-Inspiration hemophilia partnership at a value far below…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Ipsen and Inspiration Biopharmaceuticals hemophilia partnership: Ipsen took 20% stake for $85M, plus up to $174M for additional 27% stake based on milestones (total $259M). Inspiration later filed Chapter 11 in 2012.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen SA / Inspiration Biopharmaceuticals, Inc. (this deal) | 2010 | $259M | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2010 deals · Hematology deals